PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Infigratinib→

Infigratinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
872511-34-7
Molecular formula
C26H31Cl2N7O3
Molecular weight
560.48 g/mol
Drug class
Fibroblast growth factor receptor (FGFR) 1-3 tyrosine kinase inhibitortargeted antineoplastic (withdrawn US indication)
Mechanism of action
Inhibits FGFR1, FGFR2 and FGFR3 tyrosine kinase activity, reducing downstream signalling in tumours driven by susceptible FGFR alterations.
Indications / reported uses
  • Historical US indication: treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement. US approval of Truseltiq was withdrawn 16 May 2024; do not list as a current US-authorised treatment.

Sources: US FDA — Withdrawn cancer accelerated approvals · Federal Register — Withdrawal of Truseltiq approval · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Infigratinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Infigratinib Permitted Daily Exposure (PDE) report (the Infigratinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Infigratinib Occupational Exposure Limit (OEL) report (the Infigratinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.